Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

Last week, two of the biggest and oldest companies in the burgeoning AI drug discovery space announced a surprise merger. In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes ...

How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

New experiments suggest that freezing and thawing on early Earth may have helped primitive cell-like structures grow and evolve. Tiny lipid bubbles behaved very differently depending on their membrane ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

HUMANS HAVE never been immune from the pressures of natural selection. Throughout the history of the species circumstances have arisen to give individuals with certain beneficial mutations an ...

RXRX is trading near the bottom of its 52-week range and below its 200-day simple moving average. Price change The price of RXRX shares has decreased $0.11 since the market last closed. This is a 3.37 ...

Natural selection has been playing a bigger role in changing modern human DNA than previously thought, according to a new study. geralt via Wikimedia Commons under CC0 Many people are familiar with ...

Clonal selection is a process proposed to explain how a single B or T cell that recognizes an antigen that enters the body is selected from the pre-existing cell pool of differing antigen ...

A good sum of two good parts. Our research team assigns Gold ratings to strategies that they have the most conviction will outperform their Morningstar Category average over a market cycle on a ...